Literature DB >> 7788936

Chondrosarcoma of the temporal bone.

G W Watters1, G B Brookes.   

Abstract

Eight patients with a chondrosarcoma of the temporal bone have been treated at the National Hospital for Neurology and Neurosurgery over a 16-year-period. Patients usually presented with symptoms and signs of lower cranial nerve palsies, though in most cases these resolved after surgery. This result, combined with the fact long-term survival can be achieved, makes surgical treatment of these tumours the best option, as the response to primary radiotherapy is uncertain. Surgical access is difficult, but an infratemporal approach is probably the most satisfactory. The use of post-operative adjuvant radiotherapy may provide some benefit. Long-term follow-up is necessary, and for this magnetic resonance imaging (MRI) is preferable to computed tomography (CT) scanning.

Entities:  

Mesh:

Year:  1995        PMID: 7788936     DOI: 10.1111/j.1365-2273.1995.tb00012.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  4 in total

1.  Fibroinflammatory pseudotumor of the temporal bone.

Authors:  M P Schönermark; P Issing; T Stöver; S Ruh; T Lenarz
Journal:  Skull Base Surg       Date:  1998

2.  Cranial chondrosarcoma and recurrence.

Authors:  Orin G Bloch; Brian J Jian; Isaac Yang; Seunggu J Han; Derick Aranda; Brian J Ahn; Andrew T Parsa
Journal:  Skull Base       Date:  2010-05

3.  Skull base chondrosarcoma: a case treated by the CyberKnife system.

Authors:  Ana Isabel Ferrer Pérez; Julio Lambea Sorrosal; María Jesús Vidal Losada; María Tobeña Puyal; Sara Serrano Solares; Manuel Ruiz-Echarri Rueda
Journal:  Clin Transl Oncol       Date:  2008-10       Impact factor: 3.405

Review 4.  Primary Skull Base Chondrosarcomas: A Systematic Review.

Authors:  Paolo Palmisciano; Ali S Haider; Mohammadmahdi Sabahi; Chibueze D Nwagwu; Othman Bin Alamer; Gianluca Scalia; Giuseppe E Umana; Aaron A Cohen-Gadol; Tarek Y El Ahmadieh; Kenny Yu; Omar N Pathmanaban
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.